[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.216.242. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
October 18, 2000

Problems in Pharmacoeconomic Analyses—Reply

Author Affiliations
 

Stephen J.LurieMD, PhD, Senior EditorIndividualAuthorPhil B.FontanarosaMD, Executive Deputy EditorIndividualAuthor

JAMA. 2000;284(15):1922-1924. doi:10.1001/jama.284.15.1921

To the Editor: The pharmaceutical industry in Australia is certainly aware that pharmacoeconomic analyses are complex and difficult to evaluate, as stated in the article by Dr Hill and colleagues,1 but we disagree with its conclusions. It is also not obvious from the article that at least 2 of the authors were involved previously in more than 1 stage of the analysis of each submission. This brings their perspective into question.

First Page Preview View Large
First page PDF preview
First page PDF preview
×